Literature DB >> 34202714

Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.

Mariangela Garofalo1, Federica Bellato1, Salvatore Magliocca1, Alessio Malfanti2, Lukasz Kuryk3,4, Beate Rinner5, Samuele Negro6, Stefano Salmaso1, Paolo Caliceti1, Francesca Mastrotto1.   

Abstract

Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with the tumor cell cytotoxicity of oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs were coated with a polygalactosyl-b-agmatyl diblock copolymer (Gal32-b-Agm29), with high affinity for the asialoglycoprotein receptor (ASGPR) expressed on the liver cell surface, exploiting the electrostatic interaction of the positively charged agmatine block with the negatively charged adenoviral capsid surface. The polymer coating altered the viral particle diameter (from 192 to 287 nm) and zeta-potential (from -24.7 to 23.3 mV) while hiding the peculiar icosahedral symmetrical OV structure, as observed by TEM. Coated OVs showed high potential therapeutic value on the human hepatoma cell line HepG2 (cytotoxicity of 72.4% ± 4.96), expressing a high level of ASGPRs, while a lower effect was attained with ASPGR-negative A549 cell line (cytotoxicity of 54.4% ± 1.59). Conversely, naked OVs showed very similar effects in both tested cell lines. Gal32-b-Agm29 OV coating enhanced the infectivity and immunogenic cell death program in HepG2 cells as compared to the naked OV. This strategy provides a rationale for future studies utilizing oncolytic viruses complexed with polymers toward effective treatment of hepatocellular carcinoma.

Entities:  

Keywords:  ASGPR; cancer therapies; cationic glycopolymers; hepatocellular carcinoma; oncolytic adenovirus; tumor targeting

Year:  2021        PMID: 34202714     DOI: 10.3390/pharmaceutics13070949

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  49 in total

1.  Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor.

Authors:  D-J Peng; J Sun; Y-Z Wang; J Tian; Y-H Zhang; M H M Noteborn; S Qu
Journal:  Cancer Gene Ther       Date:  2006-07-28       Impact factor: 5.987

2.  Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo.

Authors:  A Fasbender; J Zabner; M Chillón; T O Moninger; A P Puga; B L Davidson; M J Welsh
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

Review 3.  Oligosaccharide valency and conformation in determining binding to the asialoglycoprotein receptor of rat hepatocytes.

Authors:  K G Rice; Y C Lee
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1993

4.  The large intracellular pool of asialoglycoprotein receptors functions during the endocytosis of asialoglycoproteins by isolated rat hepatocytes.

Authors:  P H Weigel; J A Oka
Journal:  J Biol Chem       Date:  1983-04-25       Impact factor: 5.157

5.  Intratumoral injection of taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolization.

Authors:  Chaoyang Wang; Tongsheng Chen
Journal:  J Cell Biochem       Date:  2012-04       Impact factor: 4.429

6.  Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller; Magnus Jaderberg
Journal:  Cancer Gene Ther       Date:  2018-07-30       Impact factor: 5.987

Review 7.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

8.  In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.

Authors:  Yuqi Jing; Valery Chavez; Natasha Khatwani; Yuguang Ban; Andrea P Espejo; Xi Chen; Jaime R Merchan
Journal:  Cancer Gene Ther       Date:  2020-03-31       Impact factor: 5.987

9.  ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript Profile.

Authors:  Rebecca Louise Harris; Carmen Wilma van den Berg; Derrick John Bowen
Journal:  Mol Biol Int       Date:  2012-08-02

10.  Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller
Journal:  J Med Virol       Date:  2020-02-03       Impact factor: 2.327

View more
  6 in total

Review 1.  Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Authors:  Lukasz Kuryk; Giulia Rodella; Monika Staniszewska; Katarzyna Wanda Pancer; Magdalena Wieczorek; Stefano Salmaso; Paolo Caliceti; Mariangela Garofalo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

2.  Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms.

Authors:  Delia Boffoli; Federica Bellato; Greta Avancini; Pratik Gurnani; Gokhan Yilmaz; Manuel Romero; Shaun Robertson; Francesca Moret; Federica Sandrelli; Paolo Caliceti; Stefano Salmaso; Miguel Cámara; Giuseppe Mantovani; Francesca Mastrotto
Journal:  Drug Deliv Transl Res       Date:  2021-11-28       Impact factor: 5.671

Review 3.  Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.

Authors:  Weiyue Ban; Jianhuan Guan; Hanwei Huang; Zhonggui He; Mengchi Sun; Funan Liu; Jin Sun
Journal:  Nano Res       Date:  2022-02-14       Impact factor: 10.269

4.  From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.

Authors:  Mariangela Garofalo; Katarzyna Wanda Pancer; Magdalena Wieczorek; Monika Staniszewska; Stefano Salmaso; Paolo Caliceti; Lukasz Kuryk
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

Review 5.  Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment.

Authors:  Haiqiang Wang; Fan Shi; Shudan Zheng; Mei Zhao; Zimeng Pan; Li Xiong; Lihong Zheng
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

Review 6.  Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Authors:  Zhongbing Qi; Xiangyu Long; Jiyan Liu; Ping Cheng
Journal:  Front Cell Neurosci       Date:  2022-09-09       Impact factor: 6.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.